[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343271-105":59,"doc-detail-343271-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-application-of-whole-genome-sequencing-of-solid-tumors-for-precision-oncology","Clinical application of whole-genome sequencing of solid tumors for precision oncology","","Whole-genome sequencing (WGS) is presented as a practical single-assay alternative to targeted panel sequencing for precision oncology, leveraging tumor tissue and matched normal samples. A prospective single-center study evaluated real-world clinical utility in 120 patients with solid cancers, with 95 achieving report delivery within a median 11 working days. Among these, 72% generated clinically relevant insights, including therapeutic actionability and clarification of clinical questions. Reported benefits support informed therapy or active trials via driver mutations, TMB and mutational signatures, pathogenic germline variants, and inference of cancer origin.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-application-of-whole-genome-sequencing-of-solid-tumors-for-precision-oncology/343271/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-application-of-whole-genome-sequencing-of-solid-tumors-for-precision-oncology/343271.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the two primary objectives of the prospective study?","Question",{"text":112,"@type":113},"The study aims to (1) assess actionability for therapeutic options and (2) provide clarity for clinical questions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients successfully received WGS genomic reports, and how quickly were they delivered?",{"text":117,"@type":113},"Out of 120 enrolled patients, 95 (79%) successfully received genomic reports, with a median of 11 working days from sampling to reporting.",{"name":119,"@type":110,"acceptedAnswer":120},"What types of clinically relevant insights were identified in the WGS reports?",{"text":121,"@type":113},"Clinically relevant insights included therapeutic actionability based on driver mutations, tumor mutational burden and mutational signatures, pathogenic germline variants needing genetic counseling, and information to help infer cancer origin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343271,1790198294,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/emm](www.nature.com/emm)  \nARTICLE OPEN  \nClinical application of whole-genome sequencing of solid tumors for precision oncology  \nRyul Kim1,14, Seokhwi Kim2,14, Brian Baek-Lok Oh1,14, Woo Sik Yu3, Chang Woo Kim4, Hoon Hur4, Sang-Yong Son4, Min Jae Yang5, Dae Sung Cho6, Taeyang Ha7, Subin Heo7,13, Jeon Yeob Jang8, Jae Sung Yun7, Kyu-Sung Kwack7, Jai Keun Kim7, Jimi Huh7, Sun Gyo Lim5, Sang-Uk Han4, Hyun Woo Lee9, Ji Eun Park10, Chul-Ho Kim8, Jin Roh2, Young Wha Koh2, Dakeun Lee2, Jang-Hee Kim2, Gil Ho Lee5, Choong-Kyun Noh5, Yun Jung Jung10, Ji Won Park10, Seungsoo Sheen 10, Mi Sun Ahn9, Yong Won Choi9, Tae-Hwan Kim9, Seok Yun Kang9, Jin-Hyuk Choi9, Soo Yeon Baek4, Kee Myung Lee5, Sun Il Kim6, Sung Hyun Noh 11, Se-Hyuk Kim11, Hyemin Hwang9, Eunjung Joo1, Shinjung Lee1, Jong-Yeon Shin1, Ji-Young Yun1, Junggil Park1, Kijong Yi 1, Youngoh Kwon1, Won-Chul Lee1, Hansol Park1, Joonoh Lim1, Boram Yi1, Jaemo Koo1, June-Young Koh 1, Sangmoon Lee1, Yuna Lee1, Bo-Rahm Lee 1,  \nErin Connolly-Strong 1, Young Seok Ju 1 ✉ and Minsuk Kwon9,12 ✉  \n© The Author(s) 2024  \n\n|  | Genomic alterations in tumors play a pivotal role in determining their clinical trajectory and responsiveness to treatment. Targeted panel sequencing (TPS) has served as a key clinical tool over the past decade, but advancements in sequencing costs and bioinformatics have now made whole-genome sequencing (WGS) a feasible single-assay approach for almost all cancer genomes in clinical settings. This paper reports on the ﬁndings of a prospective, single-center study exploring the real-world clinical utility of WGS (tumor and matched normal tissues) and has two primary objectives: (1) assessing actionability for therapeutic options and (2) providing clarity for clinical questions. Of the 120 patients with various solid cancers who were enrolled, 95 (79%) successfully received genomic reports within a median of 11 working days from sampling to reporting. Analysis of these 95 WGS reports revealed that 72%(68/95) yielded clinically relevant insights, with 69%(55/79) pertaining to therapeutic actionability and 81%(13/ 16) pertaining to clinical clarity. These beneﬁts include the selection of informed therapeutics and/or active clinical trials based on the identiﬁcation of driver mutations, tumor mutational burden (TMB) and mutational signatures, pathogenic germline variants that warrant genetic counseling, and information helpful for inferring cancer origin. Our ﬁndings highlight the potential of WGS as a comprehensive tool in precision oncology and suggests that it should be integrated into routine clinical practice to provide a |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| complete image of the genomic landscape to enable tailored cancer management. |  |  |\n|  | Experimental & Molecular Medicine (2024) 56:1856–1868; [https://doi.org/10.1038/s12276-024-01288-x](https://doi.org/10.1038/s12276-024-01288-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nPersonalized medicine aims to customize cancer treatment strategies for each individual, ensuring interventions that yield the best patient outcomes. Central to this approach is molecular proﬁling of tumors. Molecular proﬁling has been established asan essential tool in clinical practice for identifying targetable alterations 1. Projects such as The Cancer Genome Atlas and International Cancer Genome Consortium have unveiled both prevalent and rare genetic anomalies2,3, with many presenting actionable clinical implications. These genetic deviations not only suggest viable treatment paths but also provide insights into the severity of the disease, assisting physicians in  \ncustomizing treatment plans4. For instance, the presence of ERBB2 (HER2) ampliﬁcation in breast cancers is associated with more aggressive tumor characteristics and a poorer prognosis5. However, the introduction of HER2 inhibitors, such as trastuzumab,","cbCaifMEfz8kAQwm","https://ap.wps.com/l/cbCaifMEfz8kAQwm","pdf",42820834,13,"English","# Introduction\n## Prospective study objectives and design\n## Clinical reporting outcomes and actionability\n## Genomic insights enabled by WGS","[{\"question\":\"What are the two primary objectives of the prospective study?\",\"answer\":\"The study aims to (1) assess actionability for therapeutic options and (2) provide clarity for clinical questions.\"},{\"question\":\"How many patients successfully received WGS genomic reports, and how quickly were they delivered?\",\"answer\":\"Out of 120 enrolled patients, 95 (79%) successfully received genomic reports, with a median of 11 working days from sampling to reporting.\"},{\"question\":\"What types of clinically relevant insights were identified in the WGS reports?\",\"answer\":\"Clinically relevant insights included therapeutic actionability based on driver mutations, tumor mutational burden and mutational signatures, pathogenic germline variants needing genetic counseling, and information to help infer cancer origin.\"}]","Clinical application of whole-genome sequencing of solid tumors for precision oncology | PDF",1790050525,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02d6401d05c83bef01b1d216eac13f90.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70d370169528fb8aa627b386a78c2e98.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e042afab923dc0afcd93edf85242aa76.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ee8ca7682c916d71ac3dabbb947cc94.webp",980,1301]